Intravitreal methotrexate (MTX) has been proven to be an effective treatment for various intraocular diseases. In this article, a comprehensive review was performed on intravitreal applications of methotrexate. Different aspects of the administration of intravitreal MTX for various clinical conditions such as intraocular tumors, proliferative vitreoretinopathy, diabetic retinopathy, age-related macular degeneration, and uveitis were reviewed and the adverse effects of intravitreal injection of MTX were discussed. The most common indications are intraocular lymphoma and uveitis. Other applications remain challenging and more studies are needed to establish the role of intravitreal MTX in the management of ocular diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593537 | PMC |
| http://dx.doi.org/10.18502/jovr.v16i4.9756 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review.
Eye (Lond)
December 2024
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Proliferative Vitreoretinopathy (PVR) is a major complication of surgical repair for Rhegmatogenous Retinal Detachment (RRD). Methotrexate (MTX), a folate antimetabolite, has shown promise in targeting the pathological processes involved in PVR, such as cell proliferation inhibition, fibrosis and anti-inflammation. Systematic review examines the use of MTX in PVR by analysing different administration methods and outcomes.
View Article and Find Full Text PDFIntraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatment.
Am J Ophthalmol Case Rep
December 2024
Department of Ophthalmology at University of Cincinnati, 231 Albert Sabin Way, 5th Floor, Cincinnati, OH, 45267-0527, USA.
Purpose: To present a case of aggressive proliferative vitreoretinopathy (PVR) managed with intraoperative and postoperative intravitreal methotrexate (MTX) in a patient with congenital aniridia (CI).
Observations: A 41-year-old female with a history of CI, living-related conjunctival-kerato-limbal allograft transplantation, and multiple intraocular surgeries presents with tractional retinal detachment (TRD) and aggressive grade C PVR 52 days after a primary 23-gauge pars plana vitrectomy (PPV) with rhegmatogenous retinal detachment repair. She underwent 23-gauge PPV, TRD repair including membrane peeling of pre- and sub-retinal PVR, 5000 centistoke silicone oil exchange, endolaser, and MTX infusion.
Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial-24-week Outcomes of Uveitic Macular Edema Retreatment.
Ophthalmology
November 2024
Center for Clinical Trials and Evidence Synthesis, Departments of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; Department of Ophthalmology, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Purpose: Evaluation of longer-term effectiveness of three intravitreal therapies (methotrexate, ranibizumab, or dexamethasone implant) for participants enrolled in the randomized comparative effectiveness trial the Macular Edema Ranibizumab versus Intravitreal anti-inflammatory Therapy (MERIT) Trial followed for24 weeks.
Design: Multicenter randomized controlled clinical trial with masked evaluation of retinal thickness and visual acuity.
Participants: Patients with persistent or recurrent uveitic macular edema.
Clinico-pathologic correlation in ocular sarcoidosis.
Am J Ophthalmol Case Rep
December 2024
Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Purpose: This case describes the unique course and management of a patient with progressive, refractory multi-system sarcoidosis that initially presented with ocular and dermatologic findings.
Observations: A 47-year-old male presented with acute anterior uveitis and was found to have simultaneous inflammation of his skin at a tattoo site. Diagnosis of ocular sarcoidosis was confirmed through skin biopsy.
A rare case of infiltrative optic neuropathy caused by vitreoretinal lymphoma with hyperreflective deposits in the intraretinal and subretinal pigment epithelial layers prior to the disease onset.
BMC Ophthalmol
November 2024
Department of Ophthalmology, Osaka University Graduate School of Medicine, Room E7, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan.
Background: To describe a rare case of infiltrative optic neuropathy (ION) caused by vitreoretinal lymphoma (VRL) with hyperreflective deposits in the intraretinal and subretinal pigment epithelial (RPE) layers before the disease onset.
Case Presentation: An 87-year-old Japanese female, previously treated for unexplained uveitis in the right eye, was referred for further evaluation. Despite the absence of intraocular inflammation or vitreous opacification (VO), yellowish-white deposits were noted in the macula, and OCT revealed hyperreflective deposits in the intraretinal and sub-RPE layers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!